The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 3, 2020. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.
10-Q for Q3 FY2020, filed Nov 3, 2020
The sections below describe the company as of the FY2019 annual report.
Sells tuberculosis test kits and related reagents and performs tuberculosis testing for hospitals, laboratories and public institutions.
10-K for FY2019, filed Mar 6, 2020We are a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for immunology and infectious…View ↗
We currently offer globally our T-SPOT.TB test as an in vitro diagnostic kit, meaning we sell test kits and associated accessories to…View ↗
Our customers include independent laboratories, large hospital systems and public and private institutions. Our customer relationships also…View ↗
Most revenue comes from selling test kits and accessories to distributors, institutions and laboratories, counted at a point in time; the U.K. laboratory earns service revenue when it delivers test results.
10-K for FY2019, filed Mar 6, 2020We currently offer our T-SPOT.TB test as both an in vitro diagnostic kit and a service. In the former, we sell test kits and associated…View ↗
The Company’s revenues include product and service revenues. Product revenue from diagnostic test kit sales and related accessories is…View ↗
We currently offer globally our T-SPOT.TB test as an in vitro diagnostic kit, meaning we sell test kits and associated accessories to…View ↗
$73.7M
10-K for FY2019, filed Mar 6, 2020
$73.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2019, filed Mar 6, 2020 |
95%
FY2016: 92%
|
Product, FY2019
$69.8M Sources
|
Sold outright |
|
Service
Sold outright
|
5.4%
FY2016: 8.3%
|
Service, FY2019
$3.9M Sources
|
Sold outright |
Hospitals, laboratories and public institutions buy test kits directly in the United States, China, Japan and many European countries; elsewhere, distributors market and sell the test. The U.K. laboratory tests samples sent by customers.
10-K for FY2019, filed Mar 6, 2020We currently offer globally our T-SPOT.TB test as an in vitro diagnostic kit, meaning we sell test kits and associated accessories to…View ↗
Our approach to each country is based on opportunity size, health systems characteristics and maturity of its programs to fight TB. We…View ↗
Our customers include independent laboratories, large hospital systems and public and private institutions. Our customer relationships also…View ↗
10-K for FY2019, filed Mar 6, 2020
In the year ended December 31, 2019, the Company had four customers that represented more than 10% of the Company’s total annual revenue.…View ↗
No. It lost $1.8M in FY2019.
10-K for FY2019, filed Mar 6, 2020
10-Q for Q3 FY2020, filed Nov 3, 2020
−$149KView ↗
8-K, filed Mar 8, 2021
On March 8, 2021 (the “Effective Date”), pursuant to the Implementation Agreement, dated as of January 7, 2021 (the “Implementation…View ↗
8-K, filed Apr 3, 2020
Revenues for the first quarter were near the high end of our first quarter guidance range, which was $10.7 million to $14.1 million, in…View ↗
Grew. Revenue grew 17% in 4 years, from $62.8M in FY2015 to $73.7M in FY2019, about 4% a year.
Narrower product focus
The earlier report described products and development programs for tick-borne diseases, blood screening and transplantation alongside tuberculosis. The latest report centers its offering on T-SPOT.TB, with development mainly aimed at improving that test.
10-K for FY2016, filed Mar 1, 2017 10-K for FY2019, filed Mar 6, 2020We are a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for under-served…View ↗
Our second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and…View ↗
Our third product line is a series of assays for use in blood screening, building upon our expertise in tick-borne disease. The parasite…View ↗
Our T-SPOT. CMV and T-SPOT. PRT tests are part of our fourth product line focused on the transplantation market. Both tests utilize our…View ↗
Competes with Qiagen and Diasorin
10-K for FY2019, filed Mar 6, 20202 QuantiFERON® is a registered trademark of Qiagen N.V.View ↗
Loading...
